AstraZeneca walks back some of its immuno-oncology ambition

AstraZeneca ($AZN), working to catch up with Merck ($MRK) and Bristol-Myers Squibb ($BMY) in the growing field of immuno-oncology, said its treatment is unlikely to win speedy FDA approval in lung cancer due to the presence of more advanced agents. The therapy, durvalumab, blocks the protein PD-L1 to spur an immune attack on cancer, and AstraZeneca is planning to wrap a late-stage lung cancer trial on the treatment this year. Results from that study could support an accelerated approval in the first half of next year, but AstraZeneca is cautioning investors not to bank on a quick FDA OK, Reuters reports, as the recent approvals of Merck's and Bristol-Myers' therapies in lung cancer could remove some immediacy from the agency's proceedings. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.